All In Biotech

Drug Trial Radar · NCT06105021

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Dec 2025

Study completion Dec 2029

Sponsor

Lead sponsor
Affini-T Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Solid Tumor
  • KRAS G12V

Interventions

  • AFNT-211Drug

    Engineered TCR T-Cell

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Optimal Biological Dose (OBD)Time frame: 60 months
  2. Determine the Recommended Phase 2 DoseTime frame: 60 months
  3. Incidence of Treatment Emergent Adverse EventsTime frame: 60 months
  4. Incidence of Serious Adverse EventsTime frame: 60 months
  5. Incidence of Dose Limiting ToxicitiesTime frame: 18 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Comprehensive

    Los Angeles, California

  • University of California Los Angeles Department of Medicine

    Los Angeles, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.